321 related articles for article (PubMed ID: 14760772)
1. Utility of serum CA19-9 in diagnosis of cholangiocarcinoma: in comparison with CEA.
Qin XL; Wang ZR; Shi JS; Lu M; Wang L; He QR
World J Gastroenterol; 2004 Feb; 10(3):427-32. PubMed ID: 14760772
[TBL] [Abstract][Full Text] [Related]
2. [The value of CA19-9 and CEA in predicting resectability of hilar cholangiocarcinoma].
Zong D; Zeng Y
Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Sep; 45(5):819-22. PubMed ID: 25341348
[TBL] [Abstract][Full Text] [Related]
3. Detection of serum MMP-7 and MMP-9 in cholangiocarcinoma patients: evaluation of diagnostic accuracy.
Leelawat K; Sakchinabut S; Narong S; Wannaprasert J
BMC Gastroenterol; 2009 Apr; 9():30. PubMed ID: 19405942
[TBL] [Abstract][Full Text] [Related]
4. Application of Joint Detection of AFP, CA19-9, CA125 and CEA in Identification and Diagnosis of Cholangiocarcinoma.
Li Y; Li DJ; Chen J; Liu W; Li JW; Jiang P; Zhao X; Guo F; Li XW; Wang SG
Asian Pac J Cancer Prev; 2015; 16(8):3451-5. PubMed ID: 25921161
[TBL] [Abstract][Full Text] [Related]
5. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
6. Measurement of serum carcinoembryonic antigen, carbohydrate antigen 19-9, cytokeratin-19 fragment and matrix metalloproteinase-7 for detecting cholangiocarcinoma: a preliminary case-control study.
Lumachi F; Lo Re G; Tozzoli R; D'Aurizio F; Facomer F; Chiara GB; Basso SM
Anticancer Res; 2014 Nov; 34(11):6663-7. PubMed ID: 25368272
[TBL] [Abstract][Full Text] [Related]
7. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer.
Ni XG; Bai XF; Mao YL; Shao YF; Wu JX; Shan Y; Wang CF; Wang J; Tian YT; Liu Q; Xu DK; Zhao P
Eur J Surg Oncol; 2005 Mar; 31(2):164-9. PubMed ID: 15698733
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers as a diagnostic key for hilar cholangiocarcinoma.
Juntermanns B; Radunz S; Heuer M; Hertel S; Reis H; Neuhaus JP; Vernadakis S; Trarbach T; Paul A; Kaiser GM
Eur J Med Res; 2010 Aug; 15(8):357-61. PubMed ID: 20947473
[TBL] [Abstract][Full Text] [Related]
9. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
[TBL] [Abstract][Full Text] [Related]
10. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of pancreatobiliary cancer from benign biliary strictures using neutrophil gelatinase-associated lipocalin.
Budzynska A; Nowakowska-Dulawa E; Marek T; Boldys H; Nowak A; Hartleb M
J Physiol Pharmacol; 2013 Feb; 64(1):109-14. PubMed ID: 23568978
[TBL] [Abstract][Full Text] [Related]
12. Biliary carcinoembryonic antigen levels are a marker for cholangiocarcinoma.
Nakeeb A; Lipsett PA; Lillemoe KD; Fox-Talbot MK; Coleman J; Cameron JL; Pitt HA
Am J Surg; 1996 Jan; 171(1):147-52; discussion 152-3. PubMed ID: 8554130
[TBL] [Abstract][Full Text] [Related]
13. FUT2 and FUT3 genotype determines CA19-9 cut-off values for detection of cholangiocarcinoma in patients with primary sclerosing cholangitis.
Wannhoff A; Hov JR; Folseraas T; Rupp C; Friedrich K; Anmarkrud JA; Weiss KH; Sauer P; Schirmacher P; Boberg KM; Stremmel W; Karlsen TH; Gotthardt DN
J Hepatol; 2013 Dec; 59(6):1278-84. PubMed ID: 23958938
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between clinicopathological features and CA19-9/CEA in patients with extrahepatic cholangiocarcinoma].
Tang X; Zhang J; Chen Y; Lan Z; Wang C
Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):662-6. PubMed ID: 25564055
[TBL] [Abstract][Full Text] [Related]
15. The clinical utility and limitations of serum carbohydrate antigen (CA19-9) as a diagnostic tool for pancreatic cancer and cholangiocarcinoma.
Singh S; Tang SJ; Sreenarasimhaiah J; Lara LF; Siddiqui A
Dig Dis Sci; 2011 Aug; 56(8):2491-6. PubMed ID: 21516323
[TBL] [Abstract][Full Text] [Related]
16. CA 19-9 and CEA are unreliable markers for cholangiocarcinoma in patients with primary sclerosing cholangitis.
Björnsson E; Kilander A; Olsson R
Liver; 1999 Dec; 19(6):501-8. PubMed ID: 10661684
[TBL] [Abstract][Full Text] [Related]
17. Clinical significance of serum RCAS1 levels detected by monoclonal antibody 22-1-1 in patients with cholangiocellular carcinoma.
Watanabe H; Enjoji M; Nakashima M; Noguchi K; Kinukawa N; Sugimoto R; Kotoh K; Nakamuta M; Nawata H; Watanabe T
J Hepatol; 2003 Oct; 39(4):559-63. PubMed ID: 12971966
[TBL] [Abstract][Full Text] [Related]
18. Serum CA19-9 measurement increases the effectiveness of staging laparoscopy in patients with suspected pancreatic malignancy.
Connor S; Bosonnet L; Alexakis N; Raraty M; Ghaneh P; Sutton R; Neoptolemos JP
Dig Surg; 2005; 22(1-2):80-5. PubMed ID: 15849467
[TBL] [Abstract][Full Text] [Related]
19. Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma.
Uenishi T; Yamazaki O; Tanaka H; Takemura S; Yamamoto T; Tanaka S; Nishiguchi S; Kubo S
Ann Surg Oncol; 2008 Feb; 15(2):583-9. PubMed ID: 17955299
[TBL] [Abstract][Full Text] [Related]
20. Proteomic profiling of cholangiocarcinoma: diagnostic potential of SELDI-TOF MS in malignant bile duct stricture.
Scarlett CJ; Saxby AJ; Nielsen A; Bell C; Samra JS; Hugh T; Baxter RC; Smith RC
Hepatology; 2006 Sep; 44(3):658-66. PubMed ID: 16941699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]